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Summary The log-rank test is commonly used to assess therapeutic effect in prospective, randomised clinical
trials. This test is sensitive to differences in survival between treatment groups at a specific endpoint, but
cannot determine whether such a difference is due to an enhanced cure rate or an enhanced survival time
among uncured patients. To investigate the clinical impact of such limitations, an algorithm was constructed
to simulate clinical, randomised, adjuvant therapy trials in patients with a cured fraction of 0.27 and median
survival time for uncured patients of 3.4 years. Hypothetical therapies were introduced to increase cure,
increase median survival time, or achieve a combination of these effects. For 500 simulated patients recruited
over a 5 year period and then followed for three additional years, a 50% enhancement of median survival time
(to 5.1 years) led to a survival increase detectable at the P = 0.05 level in 780 of 1000 trials, whereas 50%
enhancement of cured fraction (to 40.5%) led to a detectable increase at the same level in only 449 of 1000
trials. These findings suggest that, in clinical trials of adjuvant therapy for stage 2 breast cancer, the log rank
test may be more sensitive to increases in tumour-related survival time than to increases in cured fraction.
Randomised clinical trials of adjuvant therapy are designed
to detect a difference in survival rates than can be attributed
to the therapy under investigation. Although this difference
in survival is a paradigm of modem clinical trials, it provides
little insight into the biological processes responsible for the
change in survival rate.
At the biological level, cancer therapy can enhance survival
at a specific end-point by two distinct mechanisms: an in-
crease in cured fraction, and a lengthening of survival times
among uncured patients (Boag, 1949; Gamel et al.,1990;
Mould & Boag, 1975). Ideally, we would like to know the
impact of therapy on each of these mechanisms. To make
such a determination from survival analysis alone, however,
we would need more patients and more follow up than are
feasible for most clinical trials, as can be seen in Figure 1.
Figure la shows the impact of a 50% increase in cured
fraction for a hypothetical population of patients with stage
2 breast carcinoma, while Figure lb demonstrates the impact
on this population of a 50% increase in median survival
time. Within the 5-10 year limit of most clinical trials,
confidence intervals are too wide to allow a clear distinction
between these two survival patterns. Thus, even if a clinical
trial yields a significant difference in survival at the end of a
specified time interval, we may remain uncertain whether this
finding reflects a higher rate of cure, a prolongation of
survival time, of a combination of these mechanisms.
An important step in designing a clinical trial is estimation
of the sample size needed to have a reasonable chance of
detecting clinically significant differences in survival rates.
The likelihood of observing a statistically significant
difference in survival is referred to as the power of the trial,
and there are published tables that relate sample size, mag-
nitude of the difference to be detected, level of statistical
significance, and power desired (Freedman, 1982). For exam-
ple, a clinical trial is conducted in which patients in the
control group have a 30% survival rate. If the treatment
under study results in an improvement in survival to 45%,
then a sample size of 307 patients is required so that 80% of
such studies will have differences in survival significant at the
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Figure 1 The continuous line represents predicated survival for a
hypothetical population of patients with cured fraction of 0.27,
median survival time of 3.4 years, standard deviation log survival
time of 1.04, and a lognormal distribution of time to death from
tumour. These parameters are the same as those found by Rutqvist
for a population of 5252 patients with stage 2 breast cancer. a,
Upper broken line represents predicted survival for thispopulation,
assuming a 50% increase in cured fraction from treatment. Lower
broken line represents the difference in survival between treated
and untreated patients. b, Upper broken line represents predicted
survival for this population, assuming a 50% increase in median
survival time from treatment. Lower broken line represents the
difference in survival between treated and untreated patients.
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level of P = 0.05. To increase the power of this trial from 80
to 90%, the sample size would have to be increased to 411
patients (Freedman, 1982).
It is important to note that these sample-size estimates
were derived from standard tables, which are predicted
entirely on survival differences at a specific endpoint. Thus
these tables offer no insight into the relative impact of two
important parameters - cured fraction and median survival
time. Furthermore, there is no specific allowance for interac-
tion of these parameters with clinical covariates, such as age
ofthe patient. To overcome such limitations, we have devised
an algorithm that simulates the dynamics of patients treated
with adjuvant therapy more closely than is possible with
standard tables.
Using this algorithm, we will address the power of a
clinical trial for stage 2 breast carcinoma from a different
perspective: Given a treatment that achieves biologically
meaningful improvements in cure rate, median survival time,
or both, how does our ability to detect a statistically
significant survival difference vary as a function of number of
patients enrolled and duration of the study?
Materials and methods
The lognormal survival model
Early and important insight into mortality from cancer was
gained with the classic publication of Boag in 1949. In this
landmark article, he distinguished the role of cured fraction
from that of time to death among uncured patients. He also
showed that the distribution of time to death from many
cancers was closely approximated by a lognormal function.
Expanding upon this initial work, Rutqvist studied 14,731
patients with breast carcinoma, including a sub-population of
5.252 patients with stage 2 disease (Rutqvist et al., 1984). He
confirmed the lognormal function as a good fit to the dist-
ribution of time to death from breast carcinoma, and charac-
terised the distribution of age among patients with each stage
of breast cancer. Furthermore, he found that cured fraction
varies substantially as a function of both patient age and
tumour stage, while median survival time varies substantially
with tumour stage but only minimally with patient age. For
stage 2 patients, the overall cured fraction was 0.27 and the
median survival time was 3.4 years.
Thepopulation algorithm
This algorithm was designed to generate data sets for sur-
vival analysis of patients with stage 2 breast carcinoma. In
these sets, survival-related covariates followed essentially the
same distributions found by Rutqvist in his sub population
of 5252 patients. To achieve such distributions, patients were
randomly assigned ages that followed a Gaussian distribu-
tion, with a mean of 55.2 years and a standard deviation of
12.9 years, omitting values less than 10 years or greater than
90 years. The following regressions were used to achieve a
relationship of age to cured fraction and mean and standard
deviation of log survival time similar to that found by Rutq-
vist:
C = Cured fraction = 0.97-0.0077 Age
M = Mean log survival time = 1.42 + 0.011 Age
S = SD log survival time = 0.80 + 0.0084 Age
Therapeutic effect was determined by first randomly assig-
ning each patient to the control group (T = 0) or the treat-
ment group (T = 1). For treated patients, there was an
enhancement of cured fraction, an enhancement of median
survival time, or a combination of these effects:
Ac = Proportional therapeutic enhancement of
cured fraction
=0, 0.1, 0.2, ... 0.9, 1.0
AM = Proportional therapeautic enhancement of
median survival time
=0, 0.1, 0.2, ... 0.9, 1.0
C' = Cured fraction after treatment
=C (1+T Ac)
M' = Mean log survival time after treatment
=M+log {1+T AM}
To determine whether a patient was dead of tumour; a
random number uniformly distributed between 0 and 1 was
selected. If this number was greater than C', the patient was
considered dead of tumour at a time randomly selected from
a lognormal distribution with mean M' and standard devia-
tion S. Uniformly distributed random numbers were gener-
ated by the HP9836 BASIC algorithm, while those from a
Gaussian distribution were generated by the Box-Muller
algorithm (Hewlett-Packard, 1985; Morgan, 1984).
Note that for T = 0 or for Ac = AM=0, there is no
change in cured fraction (i.e., C' = C) or median survival
time (i.e., exp{M'} = exp{M}), while for T = Ac = AM = 1,
both parameters are increased by a factor of 2 for treated
patients (i.e., T = 1, C' = 2 C, exp{M'} = 2 exp{M}). For
Ac = AM = 0.5, both parameters are enhanced by 50 percent
for treated over untreated patients.
Allowance was also made for death from causes other than
breast carcinoma. Each patient was randomly assigned an
integer between 1 and 9. An examination was then made of
standardised survival data for the general population of
females in the United States for 1980. If, for example, a
hypothetical patient was assigned an age of 55 years and an
integer of 7, then this patient was assigned a time to death
from other causes equal to the seventh decile oftime to death
among the general female population for that age (i.e., that
time by which 70% of 55 year old women would be dead of
any cause).
Duration of followup for each patient was selected as a
random number uniformly distributed between the limits of
the study. For example, in a 5 year study with three years of
additional followup, duration of followup for each patient
would be a randomly selected line between three and eight
years, rounded to a maximum of two decimal places.
For this study, both Ac andAM were allowed to vary
between 0 and 1.0 in increments of 0.1, yielding a total of 33
possible combinations - i.e., Ac= 0 to 1.0 while AM = 0,
AM=0 to 1.0 while Ac = 0, and Ac = AM=0 to 1.0. For
each combination, a total of 1000 'clinical trials' were 'con-
ducted'. Each set of 33,000 trials was performed with the
following parameters:
Set 1: Total patients = 500, additional followup = 3
years
Set 2: Total patients = 500, additional followup = 5
years
Set 3: Total patients = 750, additional followup = 3
years.
For all trials, recruitment occured over 5 years, so that
maximum followup was either 8 years (3 years of additional
followup) of 10 years (5 years of additional followup).
For each trial, log-rank analysis was performed in the
standard fashion (Peto et al., 1977), ending each interval of
analysis at the time when one or more deaths occurred.
Results
Results are shown in Table I. It can be seen that an increase
in additional followup from 3 to 5 years enhances the ability
of the log-rank test to detect a survival difference produced
by an improvement in cured fraction, but diminishes slightly
the ability of this method to detect a survival difference
produced by enhancement in median survival time. The ex-
planation for this seemingly paradoxical effect can be dis-
covered from an examination of Figures la and lb; with
improved cured fraction alone, there is a progressive increase
in the survival difference between treated and control
patients, while with enhanced median survival time alone,
this difference declines after approximately 8 years.THERAPEUTIC CURE FOR STAGE 2 BREAST CARCINOMA 117
Table I Number of significant results (per 1000 trials) from treatment of patients with Stage 2 breast
cancer recruited over 5 years with additional followup
No. Add. yrs. Covar. Proportional increases
Cases F/U incr. 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Threshold P = 0.05
500 3 C 57 68 123 231 308 449 619 769 865 937 970
exp {M} 45 90 220 416 617 780 868 954 978 990 998
Both 56 151 442 774 931 988 999 999 1000 1000 1000
500 5 C 43 71 125 282 399 567 741 875 920 979 989
exp {M} 49 103 216 384 585 739 854 926 968 993 996
Both 42 181 499 819 949 994 999 1000 1000 1000 1000
750 3 C 50 71 145 278 444 658 774 901 962 992 997
exp {M} 42 129 307 580 798 910 973 987 998 1000 1000
Both 40 207 656 916 991 999 1000 1000 1000 1000 1000
Threshold P=0.01
500 3 C 9 18 43 84 152 217 372 537 682 824 900
exp {M} 5 22 74 210 389 573 705 841 911 952 985
Both 11 50 234 550 813 943 992 998 1000 1000 1000
500 5 C 8 17 48 117 208 337 506 701 819 920 973
exp {M} 12 25 94 181 357 519 663 802 890 954 979
Both 7 68 248 601 824 958 993 1000 1000 1000 1000
750 3 C 10 16 58 114 213 419 565 768 893 948 981
exp {M} 7 36 130 353 586 753 904 966 989 998 999
Both 7 90 407 783 955 995 1000 1000 1000 1000 1000
Discussion
The fundamental goal ofcancer therapy is to cure patients of
their entire tumour burden, so that the treated cancers pose
no further threat to life. Unfortunately, given the practical
constraints of therapeutic trials, we must rely on a secondary
measure of success - improved survival within 5 to 10 years
of initial treatment. Such an improvement, as can be seen in
Figure 1, does not assure an increase in cure rate, but rather
may reflect only an increase in survival time.
Although increased survival time is a worthy goal, its value
to the patient must be weighed against the personal and
social costs of adjuvant therapy. Women may be less willing
to spend months suffering the side-effects of cytotoxic drugs
when the potential payoff is months of extra life, rather than
a substantial increase in the likelihood of cure. This
dichotomy is especially compelling among young women, for
whom a cure can mean decades of productive and disease-
free life.
Even though several clinical trials have documented the
'benefit' of adjuvant therapy, our analysis offers no reas-
surance that modem therapy is curing a substantial portion
of women with stage 2 breast cancer. On the contrary, a
proportional increase in median survival time led to a more
consistently detected survival difference by log-rank analysis
than an increase ofequal proportion in cured fraction. Thus,
given the time constraints of many clinical trials, these detec-
table differences may reflect only a prolongation of survival
time.
It is important to note that this limitation is independent
of the level of significance achieved with the log-rank test -
i.e., an especially small P-value does not assure that a treat-
ment benefit results from enhancement of cured fraction.
Furthermore, we cannot expect better results from other
non-parametric methods of survival analysis (Peto et al.,
1977). As this article points out, the log-rank statistic is an
excellent test of the null hypothesis (no significant difference
in survival at specific endpoint), even if the hazards are not
proportional in the two treatment groups, as they were not in
our simulated populations. On the other hand, we can detect
a specific therapeutic enhancement of cured fraction with
certain parametric methods. Unfortunately, these methods
often require large data sets and prolonged followup (Boag,
1949; Gamel et al., 1990; Mould & Boag, 1975).
In closing, we must consider the limitations of this study.
The findings described above are to some extent dependent
on the model we selected. Perhaps the true parameters of
patients with stage 2 breast carcinoma differ substantially
from those parameters programmed into the hypothetical
populations studied in this report. Because ofsuch uncertain-
ties, we would not propose basic changes in the design of
clinical trials based on this evidence alone.
One conclusion, however, is clearly drawn, as can be seen
in Figure 1. With increasing followup, it becomes progres-
sively more likely that a persistent difference in survival is
due to enhanced cure rate rather than enhanced survival time
alone. Given this fact, and given the social and financial cost
of therapeutic trials, perhaps we should continue indefinitely
our efforts to obtain followup data on these patients. Impor-
tant efforts in this direction have been accomplished by the
National Cancer Data Base (USA), which represents a
nationwide collection of clinical data from selected cancers
(Steele et al., 1992) and by the Cancer Registry of Norway.
Furthermore, perhaps we should strive for the largest feasible
sample size, even if this exceeds the estimates derived from
standard tables, since this would also enhance our ability to
detect a true change in the cure rate.
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